Abiraterone, a selective androgen synthesis inhibitor, reduces androgen synthesis by inhibiting the enzyme cytochrome P450 c17 (CYP17), which is crucial in testosterone production in the adrenal glands, testes, and prostate tumors (de Bono et al., 2011). This evidence concerns the gene CYP17A1 and prostate neoplasm.